| Name | Ceftazidime Pentahydrate |
| Description | Ceftazidime Pentahydrate is a cephalosporin antibiotic with activity against gram-negative bacilli, including Pseudomonas aeruginosa, and is used in the study of infectious diseases. |
| In vitro | In Pseudomonas aeruginosa strains (PAO1, PA1, PA2), Ceftazidime pentahydrate (approximately 0-8 µg/mL; 24 h) demonstrated antibacterial and anti-biofilm activities, with minimum inhibitory concentration (MIC) values of 2-4 µg/mL[2]. |
| In vivo | In the murine thigh infection model, Ceftazidime Pentahydrate (2000 mg; administered via a 2-hour intravenous infusion every 8 hours for a total of 24 hours) was able to reduce the bacterial density against the isogenic NDM (New Delhi metallo-β-lactamase) strain[4]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Corn Oil : 3.3 mg/mL (5.18 mM), Sonication is recommended.
DMSO : 80 mg/mL (125.66 mM), Sonication is recommended.
H2O : 20 mg/mL (31.41 mM), Sonication is recommended.
|
| Keywords | β-Lactamase | thigh infection | lactamase | Inhibitor | inhibit | infection | Gram | GR-20263 | GR20263 | GR 20263 | Ceftazidime Pentahydrate | Ceftazidime | Biofilm | Bacterial | Antibiotic |
| Inhibitors Related | Neomycin sulfate | Adipic dihydrazide | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Doxycycline | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate | BES |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | EMA Approved Drug Library | Drug Repurposing Compound Library | Beta-Lactam Compound Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library | Human Metabolite Library | NMPA-Approved Drug Library |
United States
